Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for colorectal cancer prevention program in Lynch syndrome
2024-514765-19-01Phase 2Authorised
- Sponsor
- Karolinska Institutet
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hereditary nonpolyposis colorectal cancer (HNPCC), colon neoplasm and colorectal cancer (CRC) comparing Pentasa mesalazine with Placebo (2 arms). Primary endpoint: Occurrence of any colorectal neoplasia. Planned start Nov 2024; status: authorised.
02
Drugs
Salcrozine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)colon neoplasmcolorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-514765-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514765-19-01.